Novel Inhibitors of Advanced Glycation Endproducts (Part II)

Rahbar, Samuel; Yerneni, Kiran Kumar V.; Scott, Stephen; Gonzales, Noe; Lalezari, I.

doi:10.1006/mcbr.2000.0239

Cited by 60 publications

(49 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…16) Sugars (glucose and ribose) and dicarbonyl compound (MGO) are used as glycated agents, which are commonly adopted in many Maillard reaction studies. [14][15][16]24) BSA and G.K. peptide representing the amine sources could serve as targets for glycated agents. [14][15][16] The degrees of glycation are analyzed for the development of specific fluorescence, and AG is used as a positive control.…”

Section: Discussionmentioning

confidence: 99%

“…11) Synthetic products such as aminoguanidine, 12) LR compounds [13][14][15] and naturally occurring compounds such as flavonoids, 16) cinnamon bark proanthocyanidins 17) have been studied for their antiglycation activities in vitro and in vivo. The flower of the safflower plant, Carthamus tinctorius L., has been broadly used in traditional Chinese medicine for treatment of cerebrovascular and cardiovascular diseases.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Inhibitory Effects of Hydroxysafflor Yellow A on the Formation of Advanced Glycation End Products <i>in Vitro</i>

Zhuge

et al. 2012

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

To investigate the inhibitory effects of hydroxysafflor yellow A (HSYA) on the protein glycation in vitro. Using bovine serum albumin (BSA)-glucose assay, BSA-methylglyoxal (MGO) assay, and N-acetylglycyl-lysine methyl ester (G.K.) peptide-ribose assay, inhibitory effects of HSYA were investigated. Advanced glycation end products (AGEs) production was assessed by AGEs-specific fluorescence and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). In BSA-glucose assay, HSYA concentration dependently decreased AGEs formation, with maximum inhibitory effects at 1 mM by 95%. Further more, HSYA also showed significant inhibitory effects on MGO-medicated protein modification and subsequent cross-linking of proteins. Finally, when co-incubated with G.K. peptide and ribose, HSYA exhibited its antiglycation effects, and the maximum inhibitory effects of HSYA at 1 mM were 84%. Overall, our present study provides the first evidence of the antiglycation effects of HSYA on AGEs formation in vitro.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Inhibitory Effects of Hydroxysafflor Yellow A on the Formation of Advanced Glycation End Products <i>in Vitro</i>

Zhuge

et al. 2012

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…Our previous in vitro studies documented that LR-90 inhibits AGE formation, and also showed that this compound is a more potent inhibitor of AGEprotein cross-linking and post Amadori-derived AGE than aminoguanidine and pyridoxamine [27,41]. Over the last decade, evidence has accumulated implicating AGE and AGE-protein cross-linking as a major factor in the pathogenesis of diabetic nephropathy.…”

Section: Reaction Of Lr-90 With Rcsmentioning

confidence: 97%

“…These aromatic compounds, mostly derivatives of aryl (and heterocyclic) ureido, and aryl (and heterocyclic) carboxamido phenoxy isobutyric acids, were screened and evaluated using several well-established in vitro assay methods. From these screens, 29 new compounds (out of 102) with AGE-inhibitory activities were developed [27,40,41]. Using various fluorescence and immunological techniques, these compounds were found to be multistage glycation inhibitors.…”

mentioning

confidence: 99%

LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats

et al. 2003

View full text Add to dashboard Cite

Aims/hypothesis. Advanced glycation and lipoxidation endproducts have been implicated in the pathogenesis of diabetic complications, including diabetic nephropathy. LR-90, a new advanced glycation endproduct inhibitor, was investigated for its effects on the development of renal disease in diabetic rats. Methods. Diabetic animals were randomly allocated into groups receiving LR-90 or vehicle (untreated). Age-and weight-matched non-diabetic rats were studied concurrently. Body weight, plasma glucose, glycated haemoglobin, urinary albumin and creatine excretions were measured serially. Kidney histopathology, AGE accumulation in cells and tissues, protein oxidation, were also examined. In vitro assays were used to assess the possible mechanism of action of LR-90. Results. LR-90 inhibited the increase in albumin and creatinine concentrations, and concentrations of circulating AGE in diabetic rats without any effect on glycaemic control. LR-90 treated-rats also showed higher body weights than untreated diabetic rats. LR-90 prevented glomerulosclerosis, tubular degeneration and collagen deposition in the kidney. AGE-induced crosslinking and fluorescence of tail collagen were reduced by LR-90 treatment. LR-90 also decreased AGE accumulation in kidney glomeruli and nitrotyrosine deposition in the renal cortex. In vitro, LR-90 was capable of reacting with reactive carbonyl compounds and was a more potent metal chelator than pyridoxamine and aminoguanidine. Conclusion/interpretation. LR-90 reduces in vivo AGE accumulation, AGE-protein cross-linking and protein oxidation, and could be beneficial in preventing the progression of diabetic nephropathy. The AGE inhibitory and therapeutic effects of LR-90 could be attributed, at least in part, to its ability to react with reactive carbonyl species and/or potent metal chelating activity that inhibits glycoxidative-AGE formation.

show abstract

“…A number of AGE inhibitors were synthesized and screened for their AGEs inhibitory effects by Rahbar et al [173,202,203]. These are derivatives of aryl ureido and aryl carboxaminido phenoxy isobutyric acids and were derived from some known AGEs inhibitors.…”

Section: Anti-mg and Anti-ages Compoundsmentioning

confidence: 99%

Aging: Drugs to Eliminate Methylglyoxal, a Reactive Glucose Metabolite, and Advanced Glycation Endproducts

Dhar¹,

Desai²

2012

Pharmacology

View full text Add to dashboard Cite

Novel Inhibitors of Advanced Glycation Endproducts (Part II)

Cited by 60 publications

References 44 publications

Inhibitory Effects of Hydroxysafflor Yellow A on the Formation of Advanced Glycation End Products <i>in Vitro</i>

Inhibitory Effects of Hydroxysafflor Yellow A on the Formation of Advanced Glycation End Products <i>in Vitro</i>

LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats

Aging: Drugs to Eliminate Methylglyoxal, a Reactive Glucose Metabolite, and Advanced Glycation Endproducts

Contact Info

Product

Resources

About